Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country

Growth Factors

Volumn 30, Issue 3, 2012, Pages 158-166

  Reyes, L M ^a   Garcia R G ^b   Ruiz, S L ^b   Broadhurst, D ^a   Aroca, G ^c   Davidge, S T ^a   Lopez Jaramillo P ^d,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^c Clínica de la Costa   (Colombia)

^d UNIVERSIDAD DE SANTANDER   (Colombia)

^e Research Institute of the Fundacion Oftalmologica de Santander FOSCAL   (Colombia)

Author keywords

Angiogenesis; Lipid alterations; Pathophysiology; Preeclampsia

Indexed keywords

ENDOGLIN; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; DELIVERY; DEVELOPING COUNTRY; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARITY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLOMBIA; DEVELOPING COUNTRIES; FEMALE; HUMANS; LIPOPROTEINS, LDL; NEOVASCULARIZATION, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84861379455     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.674035     Document Type: Article

References (46)

1. AbouZahr C. 2003. Global burden of maternal death and disability. Br Med Bull 67:1-11.
2. ACOG Committee on Obstetric Practice 2002. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians andGynecologists. Int JGynaecolObstet. 77:67-75.
3. Aggarwal PK, Jain V, Sakhuja V, Karumanchi SA, Jha V. 2006. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 69:621-624.
4. Ahmad S, Ahmed A. 2004. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95:884-891.
5. Benyo DF, Miles TM, Conrad KP. 1997. Hypoxia stimulates cytokine production by villous explants from the human placenta. J Clin Endocrinol Metab 82:1582-1588.
6. Bermudez OI, Tucker KL. 2003. Trends in dietary patterns of Latin American populations. Cadernos de saude publica/Ministerio da Saude, Fundacao Oswaldo Cruz. Escola Nacional de Saude Publica 19(Suppl 1):S87-S99.
7. Burton GJ,Woods AW, Jauniaux E, Kingdom JC. 2009. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30:473-482.
8. Cekmen MB, Erbagci AB, Balat A, Duman C, Maral H, Ergen K, Ozden M, Balat O, Kuskay S. 2003. Plasma lipid and lipoprotein concentrations in pregnancy induced hypertension. Clin Biochem 36:575-578.
9. De Wolf F, Brosens I, Robertson WB. 1982. Ultrastructure of uteroplacental arteries. Contrib Gynecol Obstet 9:86-99.
10. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE. 2008. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet. 102:146-151.
11. Druzin ML, Charles B, Johnson AL. 2008. Editorial summary of symposium on hypertensive disorders of pregnancy. Curr Opin Obstet Gynecol 20:91.
12. GanzevoortW, Rep A, Bonsel GJ, de Vries JI,Wolf H. 2004. Plasma volume and blood pressure regulation in hypertensive pregnancy. J Hypertens 22:1235-1242.
13. Garcia RG, Celedon J, Sierra-Laguado J, Alarcon MA, Luengas C, Silva F, Arenas-Mantilla M, Lopez-Jaramillo P. 2007. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens 20: 98-103.
14. Herrera JA, Parra B, Herrera E, Botero JE, Arce RM, Contreras A, Lopez-Jaramillo P. 2007. Periodontal disease severity is related to high levels of C-reactive protein in pre-eclampsia. J Hypertens 25:1459-1464.
15. Hung TH, Skepper JN, Burton GJ. 2001. In vitro ischemiareperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies. Am J Pathol 159: 1031-1043.
16. Khan KS,Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. 2006. WHO analysis of causes of maternal death: A systematic review. Lancet 367:1066-1074.
17. Kita N, Mitsushita J. 2008. A possible placental factor for preeclampsia: sFlt-1. Curr Med Chem 15:711-715.
18. Kulkarni AV, Mehendale SS, Yadav HR, Kilari AS, Taralekar VS, Joshi SR. 2010. Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens Res. 33:561-567.
19. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS. 2009. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 22: 1021-1038.
20. Lee H, Park H, Kim YJ, Kim HJ, Ahn YM, Park B, Park JH, Lee BE. 2005. Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in human preeclamptic placenta: Possible implications in the process of trophoblast apoptosis. Placenta 26:226-233.
21. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA, CPEPStudy Group. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005.
22. Lopez-Jaramillo P, Pradilla LP, Castillo VR, Lahera V. 2007. Socioeconomic pathology as a cause of regional differences in the prevalence of metabolic syndrome and pregnancy-induced hypertension. Rev Esp Cardiol 60:168-178.
23. Lopez-Jaramillo P, Herrera JA, Arenas-Mantilla M, Jauregui IE, Mendoza MA. 2008. Subclinical infection as a cause of inflammation in preeclampsia. Am J Therapeut 15:373-376.
24. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. 1994. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 101:669-674.
25. Ministerio de la protección socia.l. 2009 Panorama de la mortalidad materna en Colombia, 1995-2000: Logros, fracasos, compromisos y retos (parte II), Boletín epidemiológico semanal SIVIGILA Instituto Nacional De Salud.
26. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J, Jr. 2010. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with preeclampsia. Hypertens Res 33:892-898.
27. National High Blood Pressure Education Program 2000. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 183:S1-S22.
28. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. 2006. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol. 291:R1085-R1093.
29. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A. 1991. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 98:648-655.
30. Qiu C, Phung TT, Vadachkoria S, Muy-Rivera M, Sanchez SE, Williams MA. 2006. Oxidized low-density lipoprotein (Oxidized LDL) and the risk of preeclampsia. Physiol Res/Academia Scientiarum Bohemoslovaca 55:491-500.
31. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. 2012. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125:911-919.
32. Ray JG, Diamond P, Singh G, Bell CM. 2006. Brief overview of maternal triglycerides as a risk factor for pre-eclampsia. BJOG Int J Obstet Gynaecol 113:379-386.
33. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN, Jr, Bennett WA. 1999. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 181:915-920.
34. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. 2006. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 195:255-259.
35. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. 2008. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 21: 9-23.
36. Sanchez SE, Williams MA, Muy-Rivera M, Qiu C, Vadachkoria S, Bazul V. 2005. A case-control study of oxidized low density lipoproteins and preeclampsia risk. Gynecol Endocrinol. 21: 193-199.
37. Sankaralingam S, Xu Y, Sawamura T, Davidge ST. 2009. Increased lectin-like oxidized low-density lipoprotein receptor-1 expression in the maternal vasculature of women with preeclampsia: Role for peroxynitrite. Hypertension 53:270-277.
38. Shokry M, Bedaiwy MA, Fathalla MM, Alsemary A, Elwakil S, Murphy A. 2010. Maternal serum placental growth factor and soluble fms-like tyrosine kinase 1 as early predictors of preeclampsia. Octa Obstet Gynecol Scand 89:143-146.
39. Sibai BM. 2003. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 102:181-192.
40. Srinivas SK, Larkin J, Sammel MD, Appleby D, Bastek J, Andrela CM, Ofori E, Elovitz MA. 2010. The use of angiogenic factors in discriminating preeclampsia: Are they ready for prime time?. J Matern Fetal Neonatal Med. 23:1294-1300.
41. Varughese B, Bhatla N, Kumar R, Dwivedi SN, Dhingra R. 2010. Circulating angiogenic factors in pregnancies complicated by pre-eclampsia. Natl Med J India 23:77-81.
42. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12:642-649.
43. Verlohren S, Galindo A, SchlembachD, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. 2010. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202:161e1-161e11.
44. Von Dadelszen P, Magee LA, Roberts JM. 2003. Subclassification of preeclampsia. Hypertens Pregnancy. 22:143-148.
45. Wang A, Rana S, Karumanchi SA. 2009. Preeclampsia: The role of angiogenic factors in its pathogenesis. Physiology (Bethesda, Md.) 24:147-158.
46. Witztum JL. 1993. Susceptibility of low-density lipoprotein to oxidative modification. Am J Med 94:347-349.